GPR55 is another GPCR, known as an LPI receptor and a putative endocannabinoid receptor, and is a peripheral target for diabetes treatment because GPR55 agonists have insulinotropic activity [22,23,24,34]. This evidence concerns the gene LPAR3 and diabetes mellitus.